Fulcrum Therapeutics, Inc. Cash Flow Statement

Cash Flow Statement Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -82.71M-70.82M-80.85M-109.87M-97.33M-9.72M
Depreciation and Depletion 1.34M2.10M2.40M2.52M2.41M2.20M1.60M
Share-based Compensation 2.16M4.22M7.35M11.07M13.35M14.80M14.55M
Gains from Sales and Divestitures 0.35M0.29M0.07M0.01M0.02M0.02M
Gains from Investment Securities 2.02M2.96M5.19M6.50M9.97M9.35M
Non-cash Items 0.31M5.77M1.48M2.12M3.23M4.35M
Cash from Operations -22.56M-39.48M-53.66M-78.48M-97.05M-90.97M-2.22M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 0.07M-0.67M-0.15M5.99M4.39M
Depreciation & Amortization (CF) 1.34M2.10M2.40M2.52M2.41M2.20M1.60M
Change in Working Capital
Change in Receivables 2.00M0.61M-2.50M0.31M1.56M
Change in Account Payables -0.02M0.80M1.77M0.97M-1.18M-0.85M-1.59M
Change in Accured Expenses 1.22M2.95M1.98M1.95M0.56M-0.82M-1.03M
Other Working Capital Changes 0.04M10.00M7.88M-13.17M-3.78M1.07M-2.00M
Investing Activities
Capital Expenditures 8.98M0.85M1.34M1.71M1.96M0.51M0.28M
Change in Intangibles 0.09M
Cash from Investing Activities -8.98M-0.94M-57.14M-129.67M12.41M-36.69M32.23M
Financing Activities
Cash from Financing Activities 105.03M64.34M71.13M186.51M84.32M118.12M2.75M
Additional items
Change in Cash 73.48M23.92M-39.66M-21.64M-0.31M-9.54M32.76M
Free Cash Flow -31.54M-40.34M-55.00M-80.19M-99.01M-91.47M-2.50M
Net Cash Flow 73.48M23.92M-39.66M-21.64M-0.31M-9.54M32.76M